Condition
Leukemia-Lymphoma, Adult T-Cell
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Recruiting2
Terminated1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01676805Recruiting
Tissue Collection for Studies of Lymph Cancer
NCT02682667Recruiting
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
NCT01000285Phase 1CompletedPrimary
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
NCT00699296Phase 2Terminated
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
Showing all 4 trials